$8.93
0[0.00%]
At close: May 22
$8.93
0[0.00%]
PreMarket: 4:00PM EDT
Latest News for 89bio Stock (NASDAQ:ETNB)
89bio Stock (NASDAQ: ETNB)
Categories: All
Wednesday, May 22, 2024
Friday, May 17, 2024
Thursday, May 16, 2024
Wednesday, May 15, 2024
Tuesday, May 14, 2024
Friday, May 10, 2024
Thursday, May 09, 2024
Monday, April 22, 2024
Wednesday, April 10, 2024
Friday, April 05, 2024
Wednesday, March 27, 2024
- HC Wainwright & Co. Maintains Buy on 89bio, Maintains $31 Price TargetBenzinga Newsdesk - Mar 27, 2024, 1:53PM
- 89bio Receives EMA PRIME Status For Pegozafermin In The Treatment Of Metabolic Dysfunction-Associated Steatohepatitis With Fibrosis And Compensated CirrhosisBenzinga Newsdesk - Mar 27, 2024, 8:16AM
Wednesday, March 13, 2024
Tuesday, March 12, 2024
Thursday, March 07, 2024
Wednesday, March 06, 2024
Tuesday, March 05, 2024
Monday, March 04, 2024
- Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - Mar 4, 2024, 1:29PM
- Cantor Fitzgerald Reiterates Overweight on 89bio, Maintains $29 Price TargetBenzinga Newsdesk - Mar 4, 2024, 10:15AM
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga Insights - Mar 4, 2024, 8:09AM
Friday, March 01, 2024
Thursday, February 29, 2024
Friday, January 12, 2024
Wednesday, December 20, 2023
Thursday, December 07, 2023
- 12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga Insights - Dec 7, 2023, 4:31PM
- 89bio Announces Pricing Of Previously Announced Upsized Underwritten Public Offering Of 15,135,135 Shares At $9.25 Per ShareBenzinga Newsdesk - Dec 7, 2023, 7:08AM
- Sprinklr Reports Downbeat Earnings, Joins Chewy, GameStop And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionAvi Kapoor - Dec 7, 2023, 5:27AM
Wednesday, December 06, 2023
Tuesday, December 05, 2023
Monday, December 04, 2023
- 89bio Outlines Roadmap For Pivotal Studies For Lead Program In Fatty Liver DiseaseVandana Singh - Dec 4, 2023, 11:38AM
- 89bio Reaches Alignment with the FDA And EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis, Program Initiation Planned in the First Half of 2024Benzinga Newsdesk - Dec 4, 2023, 7:05AM
Tuesday, November 28, 2023
Monday, November 27, 2023
Sunday, November 12, 2023
Thursday, November 09, 2023
Wednesday, November 08, 2023
Thursday, October 12, 2023
Wednesday, October 11, 2023
- Analyst Expectations for 89bio's FutureBenzinga Insights - Oct 11, 2023, 5:00PM
- 89bio shares are trading lower after RBC Capital maintained an Outperform rating on the stock but lowered its price target from $34 to $27.Benzinga Newsdesk - Oct 11, 2023, 12:48PM
- RBC Capital Maintains Outperform on 89bio, Lowers Price Target to $27Benzinga Newsdesk - Oct 11, 2023, 8:36AM
Tuesday, October 10, 2023
- Akero Therapeutics' Disappointing NASH Data Drags Its RivalVandana Singh - Oct 10, 2023, 2:48PM
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - Oct 10, 2023, 1:31PM
- Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Oct 10, 2023, 1:08PM
- PagerDuty, John Wiley & Sons, Ventyx Biosciences And Other Big Stocks Moving Lower On TuesdayLisa Levin - Oct 10, 2023, 11:37AM